Recursion Pharmaceuticals (RXRX) Research & Development (2020 - 2026)

Recursion Pharmaceuticals' Research & Development history runs 7 years deep, the most recent figure standing at $87.9 million for Q1 2026.

• Quarterly Research & Development fell 32.2% year-over-year to $87.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $433.5 million (up 15.15% YoY) and the FY2025 annual result came in at $475.3 million, up 51.16% from the prior year.
• Research & Development was $87.9 million for Q1 2026 at Recursion Pharmaceuticals, down from $95.9 million in the prior quarter.
• Across five years, Research & Development topped out at $129.6 million in Q1 2025 and bottomed at $32.4 million in Q1 2022.
• A 5-year average of $75.0 million and a median of $70.0 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2025 — Research & Development surged 91.88% — and 2026, when it tumbled 32.2%.
• Recursion Pharmaceuticals' Research & Development stood at $44.0 million in 2022, then surged by 57.99% to $69.5 million in 2023, then soared by 41.52% to $98.3 million in 2024, then decreased by 2.43% to $95.9 million in 2025, then fell by 8.38% to $87.9 million in 2026.
• Business Quant data shows RXRX's Research & Development at $87.9 million in Q1 2026, $95.9 million in Q4 2025, and $121.1 million in Q3 2025.